🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Canada / NCT05924646
Recruiting Not applicable

CAlgary SAlt for POTS

NCT05924646 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-05-07
Last updated
2026-05-07

Condition(s) studied

Postural Orthostatic Tachycardia Syndrome

Investigational drug(s) / intervention(s)

Sodium Chloride CapsulesMicrocystalline Cellulose Capsules

Sodium Chloride Capsules: Table salt in slow release capsules.

Microcystalline Cellulose Capsules: Microcrystalline Cellulose Capsules (Placebo)

Study summary

Many patients with postural orthostatic tachycardia syndrome (POTS) have decreased plasma volume. Current POTS guidelines recommend \~10 g of salt and 2-3 L of fluid per day. Despite this recommendation, there is no long term data evaluating the use of salt in POTS. This randomized, placebo-controlled cross-over trial will evaluate a high salt diet, compared to a normal salt diet over a period of 3 months. Participants will complete 3 in lab evaluations including autonomic function testing, tilt table testing, blood volume and urine sodium evaluation, plasma catecholamine measurements and and cytokine measurements.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Physician Diagnosis of POTS as defined by the CCS Consensus Statement and as follows: * Sustained, excessive orthostatic tachycardia ≥ 30 bpm within 10 minutes standing. * Absence of orthostatic hypotension (\>20/10 mmHg decrease) within 3 minutes standing. * Chronic orthostatic symptoms that improve with recumbence. * Age 18-60 years old. * Ability to attend the Calgary Autonomic Research Clinic in Calgary. * Resident of Canada Exclusion Criteria: * Overt cause for postural tachycardia (i.e., acute dehydration, thyroid disease) * Participants with somatization or severe anxiety symptoms will be excluded * Pregnant (self-reported) * Underlying causes of tachycardia including acute hypovolemia, endocrinopathy, anemia, anxiety, medication effects, recreational drug effects, and prolonged bedrest. * Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies * Fludrocortisone use (due to effects on renal Na+ handling) * Patients who have received IV saline in the 2 months preceding the study or who plan to receive it during the course of the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Calgary Calgary Alberta Recruiting

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05924646 on ClinicalTrials.gov ↗ ← All trials in Canada